Prostate Cancer — An Interview with Prof Karim Fizazi

Featuring an interview with Prof Karim Fizazi, including the following topics:

• Perspectives on the PROTEUS Phase III trial evaluating the addition of apalutamide to standard therapy for high-risk localized prostate cancer (0:00)
• Mechanism of action of opevesostat and potential role in castration-resistant prostate cancer with androgen receptor mutations (15:37)
• Perspectives on alpha- and beta-emitting radiopharmaceuticals in the treatment of prostate cancer (22:47)
• Novel antibody-drug conjugates and proteolysis-targeting chimeras (30:43)
• Treatment approaches for metastatic hormone-sensitive prostate cancer — de novo symptomatic presentation versus PSMA-only metastatic recurrence after local therapy (34:51)
• Role of intermittent therapy in the treatment of prostate cancer (38:48)
• Treatment intensification approaches in prostate cancer (41:38)
• Case: A man in his late 60s with de novo PSMA PET-positive metastatic castration-sensitive prostate cancer (45:25)

CME information and select publications